Table 8.
Diagnostic effectiveness of the anti-MCV test.
| Anti-MCV titer best cut-off value = 20.5 U/L | |
|---|---|
| Sensitivity | 79.6% |
| Specificity | 96.6%* |
| PPV | 96.22%, 95% CI = 87.24% |
| NPV | 81.42%, 95%, CI = 87.24% |
| Accuracy | 87.80% |
| Positive DLR | 23.50 (+ve odds ratio) |
| Negative DLR | 0.21 (−ve odds ratio) |
| Prevalence | 52.03% |
| Pre-test odds/probability | 1.08 |
| post-test odds +ve | 25.49 |
| TPFN ratio | 3.9231 |
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; DLR, diagnostic likelihood ratio (odds ratio); TPF N, the proportion of true positives to false negatives for the test condition; Pre-test odds/probability, the odds/probability of the condition (prevalence) in the whole community.16
*
Out of the 29 SLE patients; four were tested positive for the anti-MCV test (13.7%), as did one of the eight SpA patients and two of the six undifferentiated CT disease patients, but none of the gouty arthritis patients.